A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India

This is a multicenter, single-arm, open-label Phase 4 study evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult patients in India who have had an insufficient response, intolerance, or contraindication to triptans. It will enroll approximately 60 participants.

NCT Number	NCT07685769
Lead Sponsor	Pfizer
Conditions	Acute Treatment of Migraine
Enrollment	60 participants
Start Date	2026-07-17
Primary Completion	2028-01-11 (estimated)
Study Completion	2028-01-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-06